Opening Recap Market Pulse: Institutional flows jittered between slimming down on financial and biotech names and piling into venture debt and semis, leaving markets stuck in neutral. Key Movers: FB Financial, TriplePoint Venture...
Category - Hot Stocks
“SCLX’s Bold Move: Datavault AI Investment Just Closed!”
Introduction – SCLX and the Datavault AI Deal Scilex Holding Company (SCLX) – a small-cap pharma focused on non-opioid pain treatments – just made a striking pivot outside its core business. On September 25, Scilex announced an...
CPI Looms as Institutions Reshape Markets
Opening Recap Market Pulse: Markets crept along a narrow range yesterday as institutions quietly reshuffled holdings, sending retail investors to guess if anything big is brewing under the hood. Key Movers: Goldman Sachs...
VBVBF Earnings Call: Record Production Sparks Opportunity!
Overview: Verbio SE (OTCPK: VBVBF) – a German renewable fuels producer – recently reported record-high production volumes alongside its latest earnings call, underlining robust operational growth despite near-term profit...
Seek Stable Cash-Flow Stocks Amid Fed Uncertainty
Date: Thursday, September 25, 2025 Opening Recap Market Pulse: Markets edged higher on investors parsing quarterly results and positioning for Fed speak, dragging tech into a lull while cyclicals caught a rotation bid. Key...
CUBE Upgrade: Evercore Sees $48 Potential!
Recent Evercore Upgrade and Thesis ## CubeSmart (NYSE: CUBE) – a leading self-storage REIT – has drawn fresh attention after Evercore ISI upgraded the stock to “Outperform” with a $48 price target ([1]). Evercore’s call implies...
Health-Tech Stocks Ignite as Funds Dump Industrials
Market Pulse: Small-cap health-tech stocks tore higher as big asset managers reallocated from industrials into faster-moving names. The rotation shows a clear pivot away from yesterday’s compounders. Key Movers: Diversified Trust...
MNPR: $135M Offering Sparks Game-Changing Potential!
Company Overview & Pipeline Monopar Therapeutics (NASDAQ: MNPR) is a clinical-stage biopharma focused on two distinct areas: a late-stage rare disease drug and early-stage radiopharmaceutical cancer therapies. Its lead asset is...
Tech Hype Fades as Yield Plays Surge
Daily Financial Update Market Pulse: Markets drift as institutional investors recalibrate portfolios in the wake of heavy Q2 filings and PhonePe’s improved earnings outlook. Key Movers: PhonePe’s FY25 results headline gains for...
NTLA: JMP Securities Just Rated It “Market Perform”!
Company Overview Intellia Therapeutics (NASDAQ: NTLA) is a clinical-stage biotechnology company pioneering CRISPR/Cas9 gene editing therapies for severe diseases ([1]). The company’s pipeline includes in vivo gene-editing...